<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092024000100027</article-id>
<article-id pub-id-type="doi">10.35366/115678</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Procalcitonina versus dímero D como predictores de mortalidad en sepsis]]></article-title>
<article-title xml:lang="en"><![CDATA[Procalcitonin versus dimer D as predictors of mortality in sepsis]]></article-title>
<article-title xml:lang="pt"><![CDATA[Procalcitonina versus D-dimero como preditores de mortalidade na sepse]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guzmán Herrera]]></surname>
<given-names><![CDATA[Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Secretaría de Salud Hospital General La Villa ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>38</volume>
<numero>1</numero>
<fpage>27</fpage>
<lpage>34</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092024000100027&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092024000100027&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092024000100027&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  se considera que hasta 50% de las camas en la Unidad de Cuidados Intensivos (UCI) son ocupadas por pacientes con sepsis. La sepsis es la causa más común de muertes intrahospitalarias y cuesta más de 24 mil millones de dólares al año a nivel mundial.  Objetivo:  demostrar que el dímero D es mejor que la procalcitonina para predecir la mortalidad en pacientes con sepsis.  Material y métodos:  estudio observacional, descriptivo, longitudinal, ambispectivo, comparativo y analítico. Fueron incluidos pacientes que ingresaron con criterios de sepsis a la Unidad de Cuidados Intensivos Adultos, del Hospital General La Villa de la Secretaría de Salud de la Ciudad de México. El periodo de estudio fue de abril de 2022 a junio de 2023.  Resultados:  se revisaron 250 expedientes de los cuales se seleccionaron 66 pacientes. La media de edad fue de 50 ± 15.3 años; 54.5% (n = 36) correspondieron al sexo masculino. La mediana de días de estancia intrahospitalaria fue de cuatro (rango: 2-7.25). La mediana de procalcitonina inicial, 7.4 ng/mL (rango: 3.3-43.3); la mediana de procalcitonina a las 24 horas, 11.3 ng/mL (rango: 5.8-51.8); la mediana de dímero D inicial, 2,400 µm/mL (rango: 1,487-3,772); la mediana de dímero D a las 24 horas, 3,175 µm/mL (rango 1,665-4,554). Entre las comorbilidades se registraron: diabetes mellitus (33.3%, n = 22), hipertensión arterial sistémica (27.3%, n = 18), hepatopatía (6.1%, n = 4), enfermedad renal crónica (4.5%, n = 3), embarazo (4.5%, n = 3), neoplasias (1.5%, n = 1), cardiopatía (1.5%, n = 1). La mortalidad fue de 37.9%. Se realizó un análisis multivariado de riesgo, con gráfico de supervivencia Kaplan-Meier, y se observó procalcitonina inicial con OR 1.71 (IC95% 1.43-3.19, p = 0.045) y procalcitonina a las 24 horas, OR 0.53 (IC95% 0.620-2.37, p = 0.063); el dímero D inicial &gt; 500 µm/mL obtuvo un OR 1.40 (IC95% 1.27-2.72, p = 0.030) y el dímero D a las 24 horas que continúo elevado &gt; 500 registró un OR 2.0 (IC95% 1.62-2.36, p = 0.004).  Conclusiones:  la procalcitonina tiene mayor impacto en la mortalidad que el dímero D. El dímero D tiene igual impacto que la procalcitonina en la mortalidad a las 24 horas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  it is considered that up to 50% of ICU beds are occupied by patients with sepsis. Sepsis is the most common cause of in-hospital deaths, costing more than $ 24 billion annually globally.  Objective:  demonstrate that D-dimer is better than procalcitonin in predicting mortality in patients with sepsis.  Material and methods:  observational, descriptive, longitudinal, ambispective, comparative and analytical study. Study population: patients who were admitted with sepsis criteria to the Adult Intensive Care Unit of the La Villa General Hospital of the SSCDMX. Study period is from April 2022 to June 2023.  Results:  250 records were reviewed, of which 66 patients were selected. The mean age was 50 years with one (± 15.3), the male gender was (54.5%, n = 36). The median number of days of stay hospitalization was four (range: 2-7.25). The median of initial procalcitonin was 7.4 ng/mL (range: 3.3-43.3); the median of procalcitonin at 24 hours, 11.3 ng/mL (range: 5.8-51.8); the median of dimer initial D, 2,400 µm/mL (range: 1,487-3,772); median D-dimer at 24 hours, 3,175 µm/mL (range: 1,665-4,554). Among the comorbidities, Among the comorbidities were recorded: diabetes mellitus (33.3%, n = 22), systemic arterial hypertension (27.3%, n = 18), liver disease (6.1%, n = 4), chronic kidney disease (4.5%, n = 3), pregnancy (4.5%, n = 3), neoplasms (1.5%, n = 1), heart disease (1.5%, n = 1), mortality in this study was 37.9%. A multivariate risk analysis was performed, with a Kaplan-Meier survival graph, and initial procalcitonin OR 1.71 (95% CI 1.43-3.19, p = 0.045), procalcitonin at 24 hours, an OR 0.53 (95% CI 0.620-2.37, p = 0.063); the initial D-dimer greater than 500 obtained an OR 1.40 (95% CI 1.27-2.72, p = 0.030), the D-dimer greater than 500 after 24 hours obtained an OR 2.0 (95% CI 1.62-2.36, p = 0.004).  Conclusions:  procalcitonin has a greater impact on mortality than D-dimer. D-dimer has the same impact as procalcitonin on 24 hours mortality.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  considera-se que até 50% dos leitos de UTI são ocupados por pacientes com sepse. A sepse é a causa mais comum de mortes hospitalares e custa mais de US$ 24 bilhões anualmente em todo o mundo.  Objetivo:  demonstrar que o D-dímero é melhor que a procalcitonina na previsão de mortalidade em pacientes com sepse.  Material e métodos:  estudo observacional, descritivo, longitudinal, ambispectivo, comparativo e analítico. População do estudo: pacientes que foram internados com critérios de sepse na Unidade de Terapia Intensiva Adulto do Hospital Geral La Villa do SSCDMX. O período de estudo foi de abril de 2022 a junho de 2023.  Resultados:  revisaram-se 250 prontuários, dos quais foram selecionados 66 pacientes. Média de idade foi de 50 anos (± 15.3), o sexo masculino foi (54.5%, n = 36). A mediana do número de dias de internação foi de quatro (intervalo: 2-7.25); a mediana inicial da procalcitonina, 7.4 ng/mL (intervalo: 3.3-43.3); a mediana da procalcitonina às 24 horas, 11.3 ng/mL (intervalo: 5.8-51.8), a mediana do D-dimero inicial, 2,400 µm/mL (intervalo 1,487-3,772), a mediana do D-dímero às 24 horas, 3,175 µm/mL (intervalo: 1,665-4,554). Dentre as comorbidades foram registradas: diabetes mellitus (33.3%, n = 22), hipertensão arterial sistêmica (27.3%, n = 18), hepatopatia (6.1%, n = 4), doença renal crônica (4.5%, n = 3), gravidez (4.5%, n = 3), neoplasias (1.5%, n = 1), cardiopatias (1.5%, n = 1), a mortalidade neste estudo foi de 37.9%. Realizou-se uma análise de risco multivariada, com um gráfico de sobrevivência de Kaplan-Meier, e observou-se procalcitonina inicial OR 1.71 (IC95% 1.43-3.19, p = 0.045), procalcitonina em 24 horas, um OR 0.53 (IC95% 0.620-2.37, p = 0.063); o D-dímero inicial maior que 500 obteve um OR 1.40 (IC95% 1.27-2.72, p = 0.030), o D-dímero em 24 horas que permaneceu elevado acima de 500 obteve um OR 2.0 (95% IC 1.62-2.36, p = 0.004).  Conclusões:  a procalcitonina tem um impacto maior na mortalidade do que o D-dímero. O D-dímero tem o mesmo impacto que a procalcitonina na mortalidade em 24 horas.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[procalcitonina]]></kwd>
<kwd lng="es"><![CDATA[dímero D]]></kwd>
<kwd lng="es"><![CDATA[sepsis]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="en"><![CDATA[procalcitonin]]></kwd>
<kwd lng="en"><![CDATA[dimer D]]></kwd>
<kwd lng="en"><![CDATA[sepsis]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="pt"><![CDATA[procalcitonina]]></kwd>
<kwd lng="pt"><![CDATA[D-dímero]]></kwd>
<kwd lng="pt"><![CDATA[sepse]]></kwd>
<kwd lng="pt"><![CDATA[mortalidade]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Alhazzani]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Antonelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2017</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>486-552</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cella]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[de Cesaris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Locorriere]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzaroppi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nobile]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin and MR-proadrenomedullin combination with SOFA and qSOFA scores for sepsis diagnosis and prognosis: a diagnostic algorithm]]></article-title>
<source><![CDATA[Shock]]></source>
<year>2018</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rizo Amézquita]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La sepsis como causas de egreso hospitalario en México;una revisión retrospectiva 2008-2015]]></article-title>
<source><![CDATA[Boletín CONAMED-OPS]]></source>
<year>2018</year>
<volume>3</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>7-15</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Lan]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Chaou]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ann Intensive Care]]></source>
<year>2017</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>91</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manrique Abril]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mendez Fandiño]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Amaya]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Manrique-Abril]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de procalcitonina como diagnóstico de sepsis o shock séptico: revisión sistemática y metaanálisis]]></article-title>
<source><![CDATA[Infectio]]></source>
<year>2019</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-42</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klesney-Tait]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Turnbull]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Colonna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The TREM receptor family and signal integration]]></article-title>
<source><![CDATA[Nat Immunol]]></source>
<year>2006</year>
<volume>7</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1266-73</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The immunopathogenesis of sepsis]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2002</year>
<volume>420</volume>
<numero>6917</numero>
<issue>6917</issue>
<page-range>885-91</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The surviving sepsis campaign bundle: 2018 update]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2018</year>
<volume>44</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>925-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Remick]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology of sepsis]]></article-title>
<source><![CDATA[Am J Pathol]]></source>
<year>2007</year>
<volume>170</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1435-44</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Sakr]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sprung]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Ranieri]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Reinhart]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gerlach]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sepsis in European intensive care units: results of the SOAP study]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2006</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>344-53</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayashida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Aihara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamakawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Head-to-head comparison of procalcitonin and presepsin for the diagnosis of sepsis in critically ill adult patients: a protocol for a systematic review and meta-analysis]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2017</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Font]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Thyagarajan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sepsis and Septic Shock - Basics of diagnosis, pathophysiology and clinical decision making]]></article-title>
<source><![CDATA[Med Clin North Am]]></source>
<year>2020</year>
<volume>104</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>573-85</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Póvoa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mealha]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C-reactive protein as a marker of infection in critically ill patients]]></article-title>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>2005</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>101-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lippi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sepsis biomarkers: past, present and future]]></article-title>
<source><![CDATA[Clin Chem Lab Med]]></source>
<year>2019</year>
<volume>57</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1281-3</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Messmer]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Dill]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pfortmueller]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Active fluid de-resuscitation in critically ill patients with septic shock: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Eur J Intern Med]]></source>
<year>2023</year>
<volume>109</volume>
<page-range>89-96</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barichello]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Generoso]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dal-Pizzol]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2022</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhainaut]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Shorr]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Macias]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Kollef]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reinhart]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2005</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>341-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angstwurm]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Reininger]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spannagl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[D-dimer as marker for microcirculatory failure: correlation with LOD and APACHE II scores]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2004</year>
<volume>113</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>353-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anggraini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Maani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rofinda]]></surname>
<given-names><![CDATA[ZD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coagulation activity and D-dimer in sepsis patients]]></article-title>
<source><![CDATA[J Clin Pathol Med Lab]]></source>
<year>2018</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linkins]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Takach Lapner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of D-dimer testing: good, bad, and ugly]]></article-title>
<source><![CDATA[Int J Lab Hematol]]></source>
<year>2017</year>
<volume>39</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>98-103</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iba]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gando]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Murata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kushimoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saitoh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Eguchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers]]></article-title>
<source><![CDATA[J Trauma]]></source>
<year>2007</year>
<volume>63</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1093-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive values of the SOFA score and procalcitonin for septic shock after percutaneous nephrolithotomy]]></article-title>
<source><![CDATA[Urolithiasis]]></source>
<year>2022</year>
<volume>50</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>729-35</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Umemura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Aihara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamakawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Intensive Care]]></source>
<year>2019</year>
<volume>7</volume>
<page-range>22</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gai]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[BQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Research on the diagnostic effect of PCT level in serum on patients with sepsis due to different pathogenic causes]]></article-title>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2018</year>
<volume>22</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>4238-42</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios Chavarría]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sauceda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Franco Granillo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Índice procalcitonina/proteína C reactiva (PCT/PCR) como predictor de mortalidad en pacientes con choque séptico]]></article-title>
<source><![CDATA[Rev Asoc Mex Med Crít Ter Intensiva]]></source>
<year>2015</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>64-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tambo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Taguchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Okegawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fukuhara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definitions in obstructive acute pyelonephritis]]></article-title>
<source><![CDATA[BMC Urol]]></source>
<year>2020</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Visoso]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Izaguirre]]></surname>
<given-names><![CDATA[GVF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficiencia diagnóstica de la procalcitonina en sepsis y choque séptico en pacientes ingresados a la terapia intensiva]]></article-title>
<source><![CDATA[Med Crit]]></source>
<year>2019</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>84-90</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merle]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Noe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Halbwachs-Mecarelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fremeaux-Bacchi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Roumenina]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complement system part II: role in immunity]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2015</year>
<volume>6</volume>
<page-range>257</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
